AD-203 / Yuhan Corp - LARVOL DELTA

Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double- Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study. (PubMed, Gut Liver) - "The new formulation of rebamipide 150 mg (AD-203) twice daily was not inferior to rebamipide 100 mg (Mucosta) thrice daily. Both formulations showed a similar efficacy in treating erosive gastritis."

Clinical • Head-to-Head • Journal • P3 data • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Peptic Ulcer

A Study to Evaluate the Efficacy and Safety of AD-203 (clinicaltrials.gov) - P3; N=475; Completed; Sponsor: Addpharma Inc.; Not yet recruiting ➔ Completed

Clinical • Head-to-Head • Trial completion • Gastrointestinal Disorder